Interobserver variability in human papillomavirus test results in cervicovaginal cytologic specimens interpreted as atypical squamous cells.

[1]  Joan L. Walker,et al.  Predicting Absolute Risk of CIN3 During Post-Colposcopic Follow-Up: Results from the ASCUS-LSIL Triage Study (ALTS) , 2007 .

[2]  W. Lawrence,et al.  Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). , 2006, Journal of the National Cancer Institute.

[3]  C. Wheeler,et al.  A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal papanicolaou smears. , 2005, American journal of clinical pathology.

[4]  M. Schiffman,et al.  Evaluating the Risk of Cervical Precancer with a Combination of Cytologic, Virologic, and Visual Methods , 2005, Cancer Epidemiology Biomarkers & Prevention.

[5]  E. Pirog,et al.  Comparison of human papillomavirus DNA prevalence in atypical squamous cells of undetermined significance subcategories as defined by the original Bethesda 1991 and the new Bethesda 2001 Systems. , 2009, Archives of pathology & laboratory medicine.

[6]  Diane Solomon,et al.  American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer , 2003, Journal of lower genital tract disease.

[7]  Thomas C Wright,et al.  2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities. , 2002, Journal of lower genital tract disease.

[8]  M. Stoler.  Toward objective quality assurance: the eyes don't have it. , 2002, American journal of clinical pathology.

[9]  Thomas C Wright,et al.  Consensus Guidelines for the Management of Women With Cervical Cytological Abnormalities , 2002 .

[10]  Deqin Sun,et al.  Managing atypical squamous cells of undetermined significance (ASCUS): human papillomavirus testing, ASCUS subtyping,or follow-up cytology? , 2002, American journal of obstetrics and gynecology.

[11]  M. Sherman,et al.  Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. , 2001, American journal of clinical pathology.

[12]  M. Schiffman,et al.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. , 2001, JAMA.

[13]  R. Zuna,et al.  HPV DNA Testing of the Residual Sample of Liquid-Based Pap Test: Utility as a Quality Assurance Monitor , 2001, Modern Pathology.

[14]  M. Schiffman,et al.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. , 2001, Journal of the National Cancer Institute.

[15]  R. Zaino,et al.  Variance in the interpretation of cervical biopsy specimens obtained for atypical squamous cells of undetermined significance. , 2000, American journal of clinical pathology.

[16]  M. Stoler,et al.  Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. , 2000, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[17]  R. Hiatt,et al.  Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. , 1999, JAMA.

[18]  David R. Scott,et al.  Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. , 1994, American journal of clinical pathology.